-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The study reported that solid organ transplant recipients who received the new mRNA coronavirus vaccine had a lower seroconversion rate (58% after the second dose).
Based on this evidence, the French National Health Agency issued a report in April 2021.
It is recommended that immunosuppressed patients who do not respond after two doses receive a third dose of vaccine
.
Based on this evidence, the French National Health Agency issued a report in April 2021.
It is recommended that immunosuppressed patients who do not respond after two doses receive a third dose of vaccine
.
immunity
Ilies Benotmane et al.
examined the antibody response of kidney transplant recipients who did not respond to two doses and received a third dose (100 μg) of mRNA-1273 vaccine (Moderna)
.
The results of the study were published in JAMA magazine
Ilies Benotmane et al.
All kidney transplant recipients will be followed up in the Kidney Transplant Department of the University Hospital of Strasbourg from January 20, 2021 to June 3, 2021, on the day of the first vaccination and after the second vaccination In 1 month, COVID-19 and SARS-CoV-2 anti-plague IgG levels were lower than 50 arbitrary units (AU)/mL on average
.
All patients received the third dose of vaccine between April 9, 2021 and May 12, 2021
All kidney transplant recipients will be followed up in the Kidney Transplant Department of the University Hospital of Strasbourg from January 20, 2021 to June 3, 2021, on the day of the first vaccination and after the second vaccination In 1 month, COVID-19 and SARS-CoV-2 anti-plague IgG levels were lower than 50 arbitrary units (AU)/mL on average
One month after the second dose of vaccine, the IgG levels of 159 kidney transplant recipients were below 50 Au/ml
Compared with non-antibody responders, patients with a weak response after the second dose are more likely to develop an antibody response after the third dose (81.
3% and 27.
4%, respectively; the average corrected antibody titer difference is 894.
89Au/ml [95 %CI, 377.
41-1410.
37]; P=0.
001)
.
Patients taking tacrolimus, mycophenolate and steroids are less likely to develop anti-SARS-CoV-2 antibodies than patients treated with other regimens (35% and 63%, respectively; average adjusted antibody titers are poor, -697.
Compared with non-antibody responders, patients with a weak response after the second dose are more likely to develop an antibody response after the third dose (81.
This study found that the third dose of mRNA-1273 vaccine induced a serological response in 49% of kidney transplant recipients who did not respond after two doses
.
The findings of this large group of kidney transplant recipients are consistent with studies of other solid organ transplant recipients
This study found that the third dose of mRNA-1273 vaccine induced a serological response in 49% of kidney transplant recipients who did not respond after two doses
Original source
Benotmane I, Gautier G, Perrin P, et al.
Benotmane I, Gautier G, Perrin P, et al.
Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses.
JAMA.
Published online July 23, 2021.
doi:10.
1001/jama.
2021.
12339 Benotmane I, Gautier G, Perrin P, et al.
Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses.
JAMA.
Leave a message here